1. Cardillo Piccolino F, Zingirian M, Mosci C. Classification of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 1987; 225:245–50.
2. Clarkson JG, Green WR, Massof D. A histopathologic review of 168 cases of preretinal membrane. Am J Ophthalmol. 1977; 84:1–17.
Article
3. Hamilton CW, Chandler D, Klintworth GK, Machemer R. A transmission and scanning electron microscopic study of surgically excised preretinal membrane proliferations in diabetes mellitus. Am J Ophthalmol. 1982; 94:473–88.
Article
4. Taniguchi Y. Ultrastucture of newly formed blood vessels in diabetic retinopathy. Jpn J Ophthalmol. 1976; 20:19.
5. Taniguchi Y, Sameshima M, Fukiyama MM. Fine structure of retinal blood vessels in diabetic retiopathy. Nippon Ganka Gakkai Zasshi. 1972; 76:751–9.
6. Wallow IH, Geldner PS. Endothelial fenestrae in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1980; 19:1176–83.
7. Wallow IH, Greaser ML, Stevens TS. Actin filaments in diabetic fibrovascular preretinal membrane. Arch Ophthalmol. 1981; 99:2175–81.
Article
8. Tripathi RC. Fine structure of mesodermal tissues of the human eye. Trans Ophthalmol Soc U K. 1974; 94:663–95.
9. Constable IJ, Tolentino FI, Donovan RH, et al. Clinicopathologic correlation of vitreous membranes. Pruett FC, Regan CD, editors. Retina Congress. New York: Appleton-Century-Crofts;1982. p. 245–57.
10. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996; 103:1820–8.
Article
11. Hofman P, van Blijswijk BC, Gaillard PJ, et al. Endothelial cell hy-pertrophy induced by vascular endothelial growth factor in the retina. Arch Ophthalmol. 2001; 119:861–6.
Article
12. Merin S, Ber I, Ivry M. Retinal ischemia (capillary nonperfusion) in diabetic retinopathy of patients with and without systemic hypertension. Ophthalmologica. 1978; 177:76–81.
Article
13. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006; 113:1695.e1–15.
Article
14. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina. 2006; 26:1006–13.
Article
15. Mirshahi A, Roohipoor R, Lashay A, et al. Bevacizumab-aug-mented retinal laser photocoagulation in proliferative diabetic retinopathy: A randomized double-masked clinical trial. Eur J Ophthalmol. 2008; 18:263–9.
Article
16. Tonello M, Costa RA, Almeida FP, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol. 2008; 86:385–9.
Article
17. Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe PDR. Graefes Arch Clin Exp Ophthalmol. 2008; 246:837–42.